The North America Telmisartan Market would witness market growth of 5.2% CAGR during the forecast period (2020-2026). Accessibility of superior treatment alternatives for hypertension has led considerable part of the hypertensive population with regulated blood pressure.
The increasing population with cardiovascular & related disorders encourages the requirement for various antihypertensive drugs in the global market. Telmisartan is considered a non-peptide angiotensin receptor blocker that is aimed at the treatment of hypertension and other cardiovascular disorders. Telmisartan received approval from the US Food and Drug Administration (USFDA) in 1998, with an aim to treat hypertension alone or combined with other elements. This is a serious indication of how more people, each year, are vulnerable to this lifestyle disease. This, in turn, creates growth possibilities for drugs for the treatment of hypertension, and one of the key brands in the market is Telmisartan.
Some of the factors that are responsible for the growth of the Telmisartan market including rising cases of high blood pressure (hypertension), increasing geriatric population, and a surge in supportive government initiatives for increasing awareness about blood pressure diseases. Moreover, the telmisartan market would be supplemented by various factors such as increasing marketing approvals for generic forms of telmisartan, rising sedentary lifestyle, and rising occurrences of chronic diseases like kidney and diabetes. Though, the growth of the telmisartan market would suffer a decline due to the shortages of drugs. On the other hand, increasing investment in R&D activities towards telmisartan drugs in developing countries would present bright prospects during the forecast period.
The US market dominated the North America Cardiovascular Risk Reduction Market by Country in 2019, thereby, achieving a market value of $151.3 million by 2026. The Canada market is experiencing a CAGR of 8.7% during (2020 - 2026). Additionally, The Mexico market would witness a CAGR of 7.8% during (2020 - 2026).
Based on Indication, the market is segmented into Hypertension and Cardiovascular Risk Reduction. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: Telmisartan Market in North America is expected to register a CAGR of 5.2% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Cadila Healthcare Ltd. (Zydus Cadila).
Scope of the Study
Market Segments Covered in the Report:
By Indication
- Hypertension
- Cardiovascular Risk Reduction
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Aurobindo Pharma Limited
- Boehringer Ingelheim International GmbH
- Cipla Limited
- GlaxoSmithKline PLC (GSK)
- Mylan N.V.
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Cadila Healthcare Ltd. (Zydus Cadila)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Telmisartan Market, by Indication
1.4.2 North America Telmisartan Market, by Distribution Channel
1.4.3 North America Telmisartan Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Telmisartan Market by Indication
3.1 North America Hypertension Market by Country
3.2 North America Cardiovascular Risk Reduction Market by Country
Chapter 4. North America Telmisartan Market by Distribution Channel
4.1 North America Hospital Pharmacies Market by Country
4.2 North America Drug Stores and Retail Pharmacies Market by Country
4.3 North America Online Pharmacies Market by Country
Chapter 5. North America Telmisartan Market by Country
5.1 US Telmisartan Market
5.1.1 US Telmisartan Market by Indication
5.1.2 US Telmisartan Market by Distribution Channel
5.2 Canada Telmisartan Market
5.2.1 Canada Telmisartan Market by Indication
5.2.2 Canada Telmisartan Market by Distribution Channel
5.3 Mexico Telmisartan Market
5.3.1 Mexico Telmisartan Market by Indication
5.3.2 Mexico Telmisartan Market by Distribution Channel
5.4 Rest of North America Telmisartan Market
5.4.1 Rest of North America Telmisartan Market by Indication
5.4.2 Rest of North America Telmisartan Market by Distribution Channel
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Aurobindo Pharma Limited
6.2.1 Company Overview
6.2.1 Financial Analysis
6.2.2 Regional Analysis
6.2.3 Research & Development Expense
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.2.4.2 Acquisition and Mergers:
6.3 Boehringer Ingelheim International GmbH
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Approvals:
6.3.5.2 Partnerships, Collaborations, and Agreements:
6.4 Cipla Limited
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Approvals:
6.5 GlaxoSmithKline PLC (GSK)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Mylan N.V.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Product Launches and Product Expansions:
6.7 Sanofi S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.8 Sun Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Approvals:
6.8.5.2 Product Launches and Product Expansions:
6.9 Teva Pharmaceutical Industries Ltd.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expenses
6.9.5 Recent strategies and developments:
6.9.5.1 Approvals:
6.9.5.2 Product Launches and Product Expansions:
6.10. Cadila Healthcare Ltd. (Zydus Cadila)
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
6.10.5 Recent strategies and developments:
6.10.5.1 Approvals:
TABLE 1 North America Telmisartan Market, 2016 - 2019, USD Million
TABLE 2 North America Telmisartan Market, 2020 - 2026, USD Million
TABLE 3 North America Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 4 North America Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 5 North America Hypertension Market by Country, 2016 - 2019, USD Million
TABLE 6 North America Hypertension Market by Country, 2020 - 2026, USD Million
TABLE 7 North America Cardiovascular Risk Reduction Market by Country, 2016 - 2019, USD Million
TABLE 8 North America Cardiovascular Risk Reduction Market by Country, 2020 - 2026, USD Million
TABLE 9 North America Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 10 North America Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 11 North America Hospital Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 12 North America Hospital Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 13 North America Drug Stores and Retail Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 14 North America Drug Stores and Retail Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 15 North America Online Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 16 North America Online Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 17 North America Telmisartan Market by Country, 2016 - 2019, USD Million
TABLE 18 North America Telmisartan Market by Country, 2020 - 2026, USD Million
TABLE 19 US Telmisartan Market, 2016 - 2019, USD Million
TABLE 20 US Telmisartan Market, 2020 - 2026, USD Million
TABLE 21 US Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 22 US Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 23 US Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 24 US Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 25 Canada Telmisartan Market, 2016 - 2019, USD Million
TABLE 26 Canada Telmisartan Market, 2020 - 2026, USD Million
TABLE 27 Canada Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 28 Canada Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 29 Canada Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 30 Canada Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 31 Mexico Telmisartan Market, 2016 - 2019, USD Million
TABLE 32 Mexico Telmisartan Market, 2020 - 2026, USD Million
TABLE 33 Mexico Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 34 Mexico Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 35 Mexico Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 36 Mexico Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 37 Rest of North America Telmisartan Market, 2016 - 2019, USD Million
TABLE 38 Rest of North America Telmisartan Market, 2020 - 2026, USD Million
TABLE 39 Rest of North America Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 40 Rest of North America Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 41 Rest of North America Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 42 Rest of North America Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 43 Key Information – Abbott Laboratories
TABLE 44 key information – Aurobindo Pharma Limited
TABLE 45 Key Information – Boehringer Ingelheim International GmbH
TABLE 46 Key Information – Cipla Limited
TABLE 47 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 48 Key Information – Mylan N.V.
TABLE 49 Key Information – Sanofi S.A.
TABLE 50 Key Information – Sun Pharmaceutical Industries Ltd.
TABLE 51 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 52 Key Information – Cadila Healthcare Ltd.
List of Figures
FIG 1 Methodology for the research